1,5-Disubstituted Acylated 2-Amino-4,5-dihydroimidazoles as a New Class of Retinoic Acid Receptor-Related Orphan Receptor (ROR) Inhibitors

Int J Mol Sci. 2022 Apr 17;23(8):4433. doi: 10.3390/ijms23084433.

Abstract

A growing body of evidence suggests a pathogenic role for pro-inflammatory T helper 17 cells (Th17) in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, type I diabetes, and psoriasis-diseases for which no curative treatment is currently available. The nuclear retinoic acid receptor-related orphan receptors alpha and gamma (RORα/γ), in particular the truncated isoform RORγt that is specifically expressed in the thymus, play a critical role in the activation of a pro-inflammatory Th17 response, and RORγ inverse agonists have shown promise as negative regulators of Th17 for the treatment of autoimmune diseases. Our study underscores the screening of a large combinatorial library of 1,5-disubstituted acylated 2-amino-4,5-dihydroimidazoles using a demonstrated synthetic and screening approach and the utility of the positional scanning libraries strategy for the rapid identification of a novel class of ROR inhibitors. We identified compound 1295-273 with the highest activity against RORγ (3.3 µM IC50) in this series, and almost a two-fold selectivity towards this receptor isoform, with 5.3 and 5.8 µM IC50 against RORα and RORβ cells, respectively.

Keywords: ROR inhibitors; combinatorial chemistry; drug discovery; parallel synthesis.

MeSH terms

  • Arthritis, Rheumatoid*
  • Humans
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Protein Isoforms
  • Receptors, Retinoic Acid*
  • Th17 Cells

Substances

  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Protein Isoforms
  • Receptors, Retinoic Acid